Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Ophthalmology (Rochester, Minn.)

• Publication date

  2003-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0161-6420(03)00085-XPMID 12750101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION

  2002cited by this paper
• Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

  2002cited by this paper
• VEGF-initiated blood-retinal barrier breakdown in early diabetes.

  2001cited by this paper
• Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

  1999cited by this paper
• A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Radiation Therapy for Age-related Macular Degeneration.

  1999cited by this paper
• Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.

  1998cited by this paper
• Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

  1996cited by this paper
• Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes.

  1996cited by this paper
• Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.

  1996cited by this paper
• Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate.

  1996cited by this paper
• Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

  1996cited by this paper
• Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

  1995cited by this paper
• Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.

  1994cited by this paper
• Oxygen-induced retinopathy in the mouse.

  1994cited by this paper
• Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

  1994cited by this paper
• Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

  1993cited by this paper
• Molecular and biological properties of the vascular endothelial growth factor family of proteins.

  1992cited by this paper
• Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group.

  1991cited by this paper
• Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group.

  1991cited by this paper
• Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group.

  1990cited by this paper
• Vascular endothelial growth factor is a secreted angiogenic mitogen.

  1989cited by this paper
• Epidemiology of eye disease in the elderly

  1987cited by this paper
• Common causes of blindness and visual handicap in the west of Scotland.

  1983cited by this paper
• Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

  1983cited by this paper

• A system for in vitro selection of fully 2'-modified RNA aptamers.

  2025cites this paper
• The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy

  2025cites this paper
• Early detection of Parkinson's disease via aptamer-CRISPR platform.

  2025cites this paper
• In silico design and validation of high-affinity RNA aptamers for SARS-CoV-2 comparable to neutralizing antibodies

  2025cites this paper
• Identifying exudative recurrence in neovascular age-related macular degeneration using large language models

  2025cites this paper
• DNA Framework-Enabled Ocular Barrier Penetration for Microinvasive Antiangiogenic Therapy.

  2025cites this paper
• Non‐coding RNAs to treat vascular smooth muscle cell dysfunction

  2024cites this paper
• AptaDiff: de novo design and optimization of aptamers based on diffusion models

  2024cites this paper
• Photosensitizer formulations in photodynamic therapy of age-related macular degeneration.

  2024cites this paper
• Aptamer as a targeted approach towards treatment of breast cancer

  2024cites this paper
• THE ANALYSIS STUDY OF VISUAL IMPAIRMENT AND BLINDNESS DUE TO MACULAR DISEASES: A COMPREHENSIVE SYSTEMATIC REVIEW

  2024cites this paper
• Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview.

  2024cites this paper
• Aptamer-enriched scaffolds for tissue regeneration: a systematic review of the literature

  2023cites this paper
• Rapid molecular imaging of active thrombi in vivo using aptamer-antidote probes

  2023cites this paper
• Association between Oral Active-Matrix Metalloproteinase-8 Levels and Subretinal Fibrosis among Wet Age-Related Macular Degeneration Patients

  2023cites this paper
• Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases.

  2023cites this paper
• Single-molecule-binding studies of antivirals targeting the hepatitis C virus core protein

  2023cites this paper
• Mechanistic Insight into Age-Related Macular Degeneration (AMD): Anatomy, Epidemiology, Genetics, Pathogenesis, Prevention, Implications, and Treatment Strategies to Pace AMD Management

  2023cites this paper
• DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD- independent or dependent approach

  2022cites this paper
• Highly sensitive protein detection by aptamer-based single-molecule kinetic fingerprinting.

  2022cites this paper
• Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration

  2022cites this paper
• Pharmacological Aspects of Clinically Approved Gene Therapy Drugs and Products

  2022cites this paper
• Effect of Esculetin on Tert-Butyl Hydroperoxide-Induced Oxidative Injury in Retinal Pigment Epithelial Cells In Vitro

  2022cites this paper
• Clinical Effect of Tongmai Fuming Decoction on Neovascular Ophthalmopathy

  2022cites this paper
• RNA Therapeutics - Research and Clinical Advancements

  2021cites this paper
• Inhibition of thrombin activity by a covalent-binding aptamer and reversal by the complementary strand antidote.

  2021cites this paper
• Incidence of endophthalmitis following intravitreal anti VEGF injections at a tertiary care hospital in Pakistan.

  2021cites this paper
• 2D Materials-Based Aptamer Biosensors: Present Status and Way Forward.

  2021cites this paper
• Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs

  2021cites this paper
• Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles

  2021cites this paper
• Concentration Distribution of Anti-VEGF Drugs Injected Into the Vitreous Cavity of Vitrectomy and Non-vitrectomy Eyes

  2021cites this paper
• Targeted Drug Delivery: Advancements, Applications, and Challenges

  2021cites this paper
• Topical Triamcinolone Acetonide-Loaded Liposomes as Primary Therapy for Macular Edema Secondary to Branch Retinal Vein Occlusion: A Pilot Study

  2020cites this paper
• SIRTUIN 1, a novel approach in the treatment of type 2 diabetes mellitus

  2020cites this paper
• Anti-angiogenic effect of EGHB010, a standardized herbal formula of Paeoniae radix and Glycyrrhizae radix.

  2020cites this paper
• Finding relationships among biological entities

  2020cites this paper
• Therapeutic Aptamers: Evolving to Find Their Clinical Niche.

  2020cites this paper
• Impedimetric Aptamer-Based Biosensors: Applications.

  2020cites this paper
• Aucuba japonica extract inhibits retinal neovascularization in a mouse model of oxygen‐induced retinopathy, with its bioactive components preventing VEGF‐induced retinal vascular hyperpermeability

  2020cites this paper
• Aptamers used for biosensors and targeted therapy

  2020cites this paper
• Detection of prostate-specific antigen in semen using DNA aptamers: an application of nucleic acid aptamers in forensic body fluid identification.

  2020cites this paper
• Nucleotide Aptamers as Theranostic Biomaterials

  2019cites this paper
• Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.

  2019cites this paper
• Breaking down the Barrier: Topical Liposomes as Nanocarriers for Drug Delivery into the Posterior Segment of the Eyeball

  2019cites this paper
• Aptamers Chemistry: Chemical Modifications and Conjugation Strategies

  2019cites this paper
• Первый опыт трансплантации 3D-сфероидов ретинального пигментного эпителия в эксперименте

  2019cites this paper
• Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

  2019cites this paper
• Evolution and Embryonic Development

  2019cites this paper
• Anti-MUC1/CD44 Dual-Aptamer-Conjugated Liposomes for Cotargeting Breast Cancer Cells and Cancer Stem Cells.

  2019cites this paper
• Aptamers for Targeted Delivery: Current Challenges and Future Opportunities

  2019cites this paper
• Aberrant MicroRNAomics in Pulmonary Complications: Implications in Lung Health and Diseases

  2019cites this paper
• The development of transplantation technique of 3D spheroids retinal pigment epithelium in the experiment on animals

  2019cites this paper
• Dual Aptamer-Functionalized 3D Plasmonic Metamolecule for Thrombin Sensing

  2019cites this paper
• Aster koraiensis Extract and Chlorogenic Acid Inhibit Retinal Angiogenesis in a Mouse Model of Oxygen-Induced Retinopathy

  2018cites this paper
• Utilization of Apatinib-Loaded Nanoparticles for the Treatment of Ocular Neovascularization.

  2018cites this paper
• Tunable cytotoxic aptamer–drug conjugates for the treatment of prostate cancer

  2018cites this paper
• Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents

  2018cites this paper
• Copy number variation in VEGF gene as a biomarker of susceptibility to age-related macular degeneration

  2018cites this paper
• Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age‐related macular degeneration

  2018cites this paper
• Nano-Aptasensor: Strategies and Categorizing

  2018cites this paper
• A Neutralizing Aptamer to TGFBR2 and miR-145 Antagonism Rescue Cigarette Smoke- and TGF-β-Mediated CFTR Expression

  2018cites this paper
• Therapeutic aptamers in discovery, preclinical and clinical stages

  2018cites this paper
• Aptamers as Therapeutics.

  2017cites this paper
• Aptamers improve the bioactivity of biomaterials

  2017cites this paper
• NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators

  2017cites this paper
• Analyzing Relative Blood Flow Speeds in Choroidal Neovascularization Using Variable Interscan Time Analysis OCT Angiography.

  2017cites this paper
• Aptamers as promising agents in diagnostic and therapeutic applications

  2017cites this paper
• Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

  2017cites this paper
• Impacts of Aptamer Technology on Diagnostics, Biotechnology, and Therapy

  2017cites this paper
• EGHB010, a Standardized Extract of Paeoniae Radix and Glycyrrhizae Radix, Inhibits VEGF-Induced Tube Formation In Vitro and Retinal Vascular Leakage and Choroidal Neovascularization In Vivo

  2017cites this paper
• Fit for the Eye: Aptamers in Ocular Disorders

  2016cites this paper
• Prevention of accidental injection of dexamethasone intravitreal implant into the crystalline lens.

  2016cites this paper
• Intravitreal injections: A review of pharmacological agents and techniques

  2016cites this paper
• Aptamer-Mediated Selective Protein Affinity to Improve Scaffold Biocompatibility

  2016cites this paper
• Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration

  2016cites this paper
• Reliability of Intravitreal Nepafenac in Rabbits

  2015cites this paper
• Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05

  2015cites this paper
• Using RNA aptamers to manipulate the functions of Human papillomaviruses (HPV)

  2015cites this paper
• Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers

  2015cites this paper
• Cinidium officinale and its Bioactive Compound, Butylidenephthalide, Inhibit Laser-Induced Choroidal Neovascularization in a Rat Model

  2015cites this paper
• Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery

  2015cites this paper
• Age-Related Macular Degeneration: A Scientometric Analysis

  2015cites this paper
• Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor.

  2014cites this paper
• The high mobility group A1 molecular switch: turning on cancer – can we turn it off?

  2014cites this paper
• Inhibition of human neutrophil activity by an RNA aptamer bound to interleukin-8.

  2014cites this paper
• Strategies for combination of aptamer and targeted drug delivery.

  2014cites this paper
• A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD.

  2014cites this paper
• Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy

  2014cites this paper
• Chapter 13 – Shared Benefits

  2014cites this paper
• Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

  2014cites this paper
• Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival

  2014cites this paper
• TARGETING RETINAL NEOVASCULARIZATION 2

  2014cites this paper
• Systemic changes in neovascular age-related macular degeneration.

  2014cites this paper
• A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization.

  2014cites this paper
• Development of RNA aptamer-based therapeutic agents.

  2013cites this paper
• The smart targeting of nanoparticles.

  2013cites this paper
• Aptamers Targeting a Subunit or a Conformation of Glutamate Ion Channel Receptors

  2013cites this paper
• In vitro selection and characterization of single stranded DNA aptamers inhibiting the hepatitis B virus capsid-envelope interaction

  2013cites this paper
• RNA aptamers: a review of recent trends and applications.

  2013cites this paper
• Impact of Lycium Barbarum Polysaccharide and Danshensu on vascular endothelial growth factor in the process of retinal neovascularization of rabbit.

  2013cites this paper